strain
human
coronaviru
hcv
isol
studi
vitro
volunt
strain
caus
cold
volunt
cultiv
tissu
cultur
tc
produc
significantli
coryza
less
sore
throat
strain
grow
organ
cultur
oc
tc
strain
serolog
relat
isol
produc
cold
frequenc
sever
contrast
effect
test
volunt
preinfect
sera
show
preval
antibodi
increas
period
subject
neutralis
antibodi
suscept
isol
pr
associ
low
preinfect
serum
neutralis
antibodi
homolog
viru
pair
sera
frequent
show
fourfold
greater
antibodi
rise
commonli
homolog
strain
volunt
infect
immun
reinocul
strain
approxim
year
later
similar
volunt
least
partli
suscept
infect
heterolog
viru
similar
time
interv
although
strain
hcv
grown
tissu
cultur
relat
prototyp
appear
ident
heterogen
probabl
signific
factor
epidemiolog
hcv
infect
meida
tyrrel
mcintosh
et
work
human
respiratori
coronavirus
hcv
done
strain
isol
specimen
collect
hamr
procknow
isol
winter
mcintosh
et
al
effect
volunt
describ
bradburn
et
al
strain
use
number
seroepidemiolog
studi
although
antibodi
isol
appear
rel
common
virus
difficult
isol
outbreak
infect
seldom
identifi
suggest
preval
infect
fluctuat
cycl
monto
pathogen
epidemiolog
potenti
hcv
number
interrelationship
serotyp
still
poorli
understood
larson
et
al
use
organ
cultur
volunt
isol
sever
new
hcv
strain
confirm
mcintosh
suggest
coronavirus
probabl
caus
cold
adult
macleod
reed
unpublish
result
isol
strain
behaviour
new
hcv
isol
tissu
cultur
volunt
compar
differ
observ
clinic
respons
volunt
measur
serum
neutralis
antibodi
homolog
heterolog
relat
strain
use
assess
antigen
heterogen
among
group
virus
studi
volunt
seven
hcv
isol
larson
et
design
pr
ad
ro
ho
gi
pa
use
dilut
origin
nasal
wash
obtain
adult
natur
occur
cold
experi
similar
prepar
nasal
wash
collect
first
passag
viru
volunt
hu
use
inoculum
volunt
two
strain
pr
cultiv
mrcc
cell
directli
nasal
wash
produc
cytopath
effect
cpe
cell
tc
strain
third
tc
strain
ki
isol
nasal
wash
collect
studi
cold
antarctica
macleod
reed
unpublish
initi
cultiv
human
embryo
nasal
organ
cultur
two
passag
organ
cultur
mrcc
cell
passag
use
inocul
volunt
experi
tissu
cultur
three
tc
strain
use
three
success
passag
limit
dilut
mrcc
cell
strain
ad
ro
ho
gi
pa
cultiv
human
embryo
nasal
organ
cultur
despit
variou
attempt
tissu
cultur
oc
strain
viru
isol
tissu
cultur
sent
laboratori
dr
hamr
inocul
volunt
pass
human
embryo
lung
fibroblast
twice
human
embryo
nasal
tracheal
organ
cultur
six
time
sequenti
quarantin
isol
volunt
hu
nasal
wash
passag
level
hug
h
u
use
inocula
volunt
fresh
organ
culhr
passag
use
inoculum
titr
ident
puriti
inocula
use
volunt
check
tissu
cultur
serolog
studi
viru
grown
mrcc
cell
passag
three
time
limit
dilut
strain
lp
isol
natur
cold
tyrrel
et
al
inoculum
volunt
passag
hu
oc
hu
store
sinc
serolog
studi
grown
mrcc
cell
use
three
serial
passag
limit
dilut
continu
cell
line
mrcc
origin
obtain
dr
af
bradburn
grown
eagl
basal
medium
newborn
calf
serum
maintain
leibovitz
medium
glutamin
mm
foetal
bovin
serum
gentamicin
pgml
deae
dextran
pgml
viru
isol
cultur
tube
incub
roller
drum
c
cytopath
effect
read
day
inocul
viral
plaqu
demonstr
use
overlay
contain
compon
tissu
cultur
mainten
medium
agaros
incub
day
cultur
fix
formol
salin
stain
gentian
violet
human
embryo
nasal
tissu
cultur
method
base
tyrrel
blamir
use
medium
bovin
albumin
use
foetal
tissu
approv
ethic
committe
harrow
health
district
clinic
research
centr
hyperimmun
serum
prepar
rabbit
use
virion
densiti
gmml
purifi
sucros
gradient
dr
macnaughton
initi
intramuscular
inject
viru
emulsifi
freund
complet
adjuv
follow
intraven
boost
without
adjuv
hyperimmun
ascit
fluid
lp
prepar
mice
dr
af
bradburn
use
method
sommervil
neutralis
antibodi
volunt
sera
measur
micromethod
use
twofold
serum
dilut
two
replic
per
serum
tcdso
viru
x
mrcc
cell
per
well
microtitr
plate
tc
strain
except
ki
insuffici
cytopath
use
test
serum
titr
read
day
incub
highest
dilut
complet
inhibit
develop
viral
cpe
fourfold
rise
titr
preand
postinfect
sera
consid
signific
neutralis
test
anim
sera
done
test
tube
use
twofold
serum
dilut
three
tube
per
dilut
tcdso
viru
haemagglutinationinhibit
antibodi
measur
techniqu
kay
dowdl
volunt
volunt
age
came
area
uk
hous
isol
common
cold
unit
previous
describ
tyrrel
subject
made
sever
visit
unit
approxim
yearli
interv
symptom
assess
score
daili
bear
reed
day
quarantin
inocula
contain
coronaviru
control
fluid
given
nasal
drop
subject
observ
day
salineinocul
control
subject
includ
experi
clinic
evalu
done
doubl
blind
nasal
wash
viru
isol
collect
least
two
occas
second
fifth
day
inocul
depend
time
symptom
repres
viru
isol
check
neutralis
hyperimmun
rabbit
serum
prepar
viru
sera
collect
volunt
week
viru
inocul
experi
approv
ethic
committe
harrow
health
district
clinic
research
centr
strain
pr
ki
form
plaqu
mrcc
cell
fig
pr
plaqu
indistinguish
probabl
slightli
smaller
plaqu
indefinit
edg
make
measur
difficult
ki
produc
small
indistinct
plaqu
also
less
strongli
cytopath
strain
mrcc
cell
test
tube
microtitr
plate
tc
strain
pr
ki
lp
neutralis
hyperimmun
rabbit
serum
ascit
fluid
mice
immunis
lp
howev
end
point
titr
two
serolog
reagent
five
viru
strain
show
differ
consist
experi
everi
experi
lp
immun
fluid
antiserum
includ
homolog
one
heterolog
virus
use
standard
dose
five
viru
strain
rang
titr
obtain
lp
fluid
greater
rang
obtain
serum
tabl
mean
titr
lp
fluid
homolog
antigen
lp
almost
higher
heterolog
strain
pr
wherea
antiserum
differ
homolog
heterolog
pr
titr
thu
antiserum
immun
fluid
detect
differ
tc
isol
greater
abil
lp
immun
fluid
may
reflect
natur
immunis
antigen
method
immunis
coronavirus
isol
test
produc
rel
frequent
sever
cold
tabl
highest
mean
clinic
score
produc
pa
viru
isol
cytopath
mrcc
cell
two
tc
strain
pr
produc
moder
high
mean
score
viru
reisol
directli
tissu
cultur
nasal
wash
major
subject
given
strain
pair
sera
half
volunt
given
pr
show
fourfold
rise
neutralis
antibodi
titr
homolog
viru
good
correl
individu
volunt
develop
symptom
viru
reisol
antibodi
rise
eight
subject
given
pr
given
found
neutralis
antibodi
titr
homolog
viru
preinocul
sera
nasal
wash
volunt
develop
symptom
inocul
strain
ad
ro
ho
gi
pa
test
mrcc
cell
cpe
deveiop
therefor
possibl
use
homolog
strain
antigen
test
sera
volunt
receiv
virus
howev
sera
volunt
show
signific
rise
neutralis
antibodi
titr
use
pr
antigen
hi
antibodi
use
antigen
symptom
produc
tc
strain
pr
ki
compar
produc
oc
strain
ad
ro
pa
gi
ho
tabl
tc
strain
produc
coryza
significantli
often
sore
throat
less
often
oc
strain
find
correspond
observ
natur
infect
hendley
et
al
effect
volunt
studi
success
tabl
iv
year
group
subject
receiv
either
lo
dilut
origin
nasal
wash
passag
hul
viru
volunt
receiv
coronaviru
inoculum
earlier
visit
unit
includ
group
symptom
experienc
subject
indic
mean
clinic
score
decreas
success
year
proport
volunt
preinocul
neutralis
antibodi
increas
period
mean
preinocul
antibodi
titr
effect
produc
newer
hcv
isol
mark
contrast
produc
sever
differ
inocula
prototyp
tabl
v
cold
produc
period
rel
mild
thought
possibl
prolong
storag
lowtitr
inocula
might
respons
prepar
therefor
passag
twice
volunt
produc
inocula
tc
similarli
prepar
tc
store
year
passag
organ
cultur
give
higher
titr
inoculum
procedur
increas
sever
infect
produc
volunt
howev
note
volunt
possess
serum
neutralis
antibodi
anoth
tc
strain
lp
also
test
volunt
tabl
v
inoculum
store
condit
year
year
clinic
effect
much
strike
preinocul
antibodi
titr
lp
lower
hthe
differ
proport
signific
level
chisquar
test
p
antibodi
titr
mild
effect
volunt
presenc
preinocul
antibodi
subject
retrospect
studi
done
assess
whether
immun
statu
popul
chang
sinc
viru
first
isol
hamr
procknow
four
group
sera
randomli
select
among
preinocul
sera
collect
volunt
vari
month
year
sera
store
standard
condit
subject
provid
age
mean
age
group
lay
year
proport
sera
show
detect
neutralis
antibodi
declin
mean
antibodi
titr
group
rose
tabl
vi
similar
survey
hi
antibodi
period
reveal
fluctuat
level
rather
steadi
rise
clinic
effect
strain
vari
might
expect
result
neutralis
test
hyperimmun
sera
investig
serolog
divers
strain
pair
preand
postinfect
sera
volunt
develop
cold
shed
viru
inocul
strain
test
microneutralis
method
homolog
antigen
heterolog
strain
pr
fig
mean
titr
higher
pr
preinfect
postinfect
pr
fourfold
rise
common
homolog
antigen
rise
rise
pr
rise
differ
although
achiev
statist
signific
test
p
suggest
serolog
differ
exist
two
newer
strain
instanc
possibl
reinocul
individu
subject
approxim
yearli
intervai
use
differ
hcv
strain
six
subject
inocul
strain
receiv
viru
antigen
pr
x
antigen
fig
neutralis
titr
obtain
pair
sera
volunt
infect
hcv
strain
sera
test
homolog
antigento
heterolog
antigen
pr
month
later
first
inocul
cold
mean
clinic
score
high
viru
shed
easili
detect
six
subject
five
develop
antibodi
rise
second
season
six
subject
appear
complet
immun
reinocul
mean
clinic
score
viru
shed
signific
antibodi
rise
detect
eight
subject
develop
mild
moder
cold
symptom
shed
viru
inocul
lp
ki
dp
reinocul
month
later
heterolog
tc
strain
either
lp
ki
dp
contrast
immun
found
homolog
reinocul
five
eight
subject
receiv
heterolog
strain
second
occas
develop
cold
symptom
mean
clinic
score
five
shed
viru
similarli
four
volunt
develop
cold
inocul
oc
strain
pa
relat
elisa
macnaughton
challeng
month
later
tc
strain
ki
two
four
subject
develop
cold
challeng
mean
clinic
score
three
shed
viru
although
number
observ
heterolog
challeng
small
possibl
effect
natur
intercurr
infect
document
result
suggest
infect
group
viru
confer
partial
immun
subsequ
infect
anoth
strain
wherea
full
immun
homolog
reinfect
last
least
year
macnaughton
et
b
use
elisa
techniqu
pair
sera
inocul
volunt
found
isol
describ
present
studi
relat
either
although
strain
pa
ad
design
oc
cultiv
mrcc
cell
nevertheless
fell
antigen
group
thu
clearli
least
two
major
serogroup
hcv
antigen
complex
strain
alreadi
well
document
mcintosh
studi
number
oc
isol
conclud
variabl
relat
mhv
perhap
tc
strain
far
examin
relat
thought
form
rel
homogen
group
studi
detail
although
bradburn
note
minor
differ
strain
lp
present
studi
suggest
tc
strain
like
strain
ident
high
incid
hcv
infect
adult
larson
et
al
suggest
either
immun
two
major
type
individu
commun
transient
antigen
variant
exist
complet
crossprotect
perhap
possibl
appli
monto
suggest
viru
becom
preval
commun
everi
year
hypothesi
cycl
mind
inabl
obtain
minor
infect
viru
volunt
seem
surpris
becam
clear
subject
preinocul
neutralis
antibodi
preval
antibodi
appar
steadili
increas
new
isol
produc
cold
volunt
although
strain
appear
pathogen
other
tc
strain
increas
pathogen
virul
volunt
associ
low
preinocul
neutralis
antibodi
titr
homolog
viru
oc
strain
possibl
establish
whether
strainspecif
immun
statu
recipi
reason
appar
variat
strain
virul
rechalleng
experi
volunt
suggest
variou
strain
partli
crossprotect
although
immun
reinocul
strain
last
least
year
thu
present
result
suggest
exist
serolog
variant
hcv
probabl
import
bear
frequenc
sever
infect
individu
commun
divers
variant
subtyp
may
suffici
allow
rapid
success
infect
present
evid
seem
like
repeat
reinfect
singl
serotyp
neutralis
test
probabl
involv
interact
viral
surfac
elisa
also
measur
antibodi
surfacc
project
reactiv
shown
mainli
larg
glycosyl
spikeassoci
polypeptid
rather
membraneor
ribonucleoproteinassoci
polypeptid
macnaughton
et
al
neutralis
elisa
test
show
relationship
tc
strain
although
microneutralis
appear
less
sensit
elisa
kraaijeveld
et
al
gave
low
titr
volunt
sera
nevertheless
show
differ
tc
strain
reveal
elisa
appear
correspond
clinic
effect
neutralis
test
may
therefor
detect
groupspecif
subtypespecif
compon
modif
techniqu
kmetic
neutralis
test
bradburn
neutralis
organ
cultur
darbyshir
et
al
although
cumbersom
might
help
differenti
strain
although
gener
biochem
structur
coronavirus
becom
clearli
establish
siddel
et
al
yet
known
mani
antigen
determin
associ
surfac
polypeptid
hcv
extent
polypeptid
differ
hcv
strain
vari
studi
monoclon
antibodi
hcv
yet
report
may
prove
reward
defin
antigen
divers
strain
similarli
genom
analysi
aid
use
restrict
enzym
may
also
help
establish
interrelationship
virus
